secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0000899923-22-000123
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics Q2 revenue $179.3M (+7% ex-divestitures); GAAP EPS -$0.18; cuts FY EPS guidance
--------------------------------------------------------------------------------

- GAAP diluted EPS of $(0.18); adjusted EPS $0.04, down from $0.12 YoY.
- GeneSight volumes up 39% YoY; hereditary cancer volumes down 4% YoY but stabilizing.
- FY2022 revenue guidance unchanged at $670-$700M; adjusted EPS cut to $(0.10)-$0.00 from $0.00-$0.20.
- Cash $283.6M; paid $48M qui tam settlement in Q2; no debt.
- Launched Precise Oncology Solutions; liquid biopsy test via Illumina/Intermountain expected in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992322000123/0000899923-22-000123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992322000123/mygn-20220804.htm
  HTML page:      https://secwatch.observer/filing/0000899923-22-000123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer